WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013052369) NOVEL BENZIMIDAZOLE DERIVATIVES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/052369    International Application No.:    PCT/US2012/057834
Publication Date: 11.04.2013 International Filing Date: 28.09.2012
IPC:
A61K 31/4184 (2006.01), A61K 31/427 (2006.01), C07D 401/14 (2006.01), C07D 403/14 (2006.01)
Applicants: ENANTA PHARMACEUTICALS, INC. [US/US]; 500 Arsenal Street Watertown, MA 02472 (US)
Inventors: QIU, Yao-ling; (US).
WANG, Ce; (CN).
PENG, Xiaowen; (US).
CAO, Hui; (US).
YING, Lu; (CN).
GAO, Xuri; (US).
WANG, Bin; (US).
OR, Yat, Sun; (US)
Agent: ISSAC, Roy, P.; Elmore Patent Law Group 484 Groton Road Westford, MA 01886 (US)
Priority Data:
13/252,924 04.10.2011 US
Title (EN) NOVEL BENZIMIDAZOLE DERIVATIVES
(FR) NOUVEAUX DÉRIVÉS DE BENZIMIDAZOLE
Abstract: front page image
(EN)The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
(FR)La présente invention divulgue des composés de Formule (I), ou des sels, des esters ou des promédicaments de ceux-ci pharmaceutiquement acceptables, qui inhibent des virus contenant de l'ARN, en particulier le virus de l'hépatite C (HCV). Par conséquent, les composés de la présente invention interfèrent avec le cycle de vie du virus de l'hépatite C et sont aussi utiles comme agents antiviraux. La présente invention concerne en plus des compositions pharmaceutiques comprenant les composés ci-avant mentionnés pour l'administration à un sujet souffrant d'une infection par le HCV. L'invention concerne aussi des procédés de traitement d'une infection par le HCV chez un sujet par administration d'une composition pharmaceutique comprenant les composés de la présente invention.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)